

References

Books

R. Weinberg, *The Biology of Cancer*, G.S. Garland Science, 2007

S. Mukherjee, *The Emperor of All Maladies*, Scribner, 2010

Manuscripts

D. Hanahan and R. Weinberg, 2011. Hallmarks of Cancer: The Next Generation, *Cell*, 144(5):646-74.

Hayflick L., and Moorhead P.S., 1961, The serial cultivation of human diploid cell strains, *Expt Cell Res*, 25, 585-621.

Hayflick L., 2000, The future of aging, *Nature*, 408(6809):267-9.

Vogelstein, B., Lane, D. and Levine, A.J. 2000. Surfing the p53 network. *Nature*, 408(6810): 307-10.

Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A.J., Elowitz, M.B., and Alon, U., 2004. Dynamics of the p53-Mdm2 feedback loop in individual cells. *Nature Genetics*, 36:147-150.

Harris, S.A. and Levine, A.J., 2005. The p53 Pathway: Positive and Negative Feedback Loops. *Oncogene*, 24:2899-2908.

Hu, W., Feng, Z., Ma, L., Wagner, J., Rice, J.J., Stolovitzky, G., and Levine, A.J., 2007. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. *Cancer Research*, 67(6):2757-2765.

Atwal, G.S., Rabadán, R., Lozano, G., Strong, L., Ruijs, M., Schmidt, M., van'tVeer, L., Nevanlinna, L., Tommiska, J., Aittomaki, K., Bougeard, G., Frebourg, T., Levine, A.J., Bond, G., 2008. An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients. *PLoS One*, 3(4):1-7 (Epub ahead of print).

Puzio-Kuter, A.M., & Levine, A.J. 2009. Stem cell biology meets p53. *Nature Biotechnology*, 27 (10): 914-915

Levine, A.J. and Puzio-Kuter, A., 2010. The Control of the Metabolic Switch in Cancer by Oncogenes and Tumor Suppressor Genes. *Science*, 330 (6009):1340 -1344. PMID: 21127244

Mizuno, H., Spike, B.T., Wahl, G.M., Levine, A.J. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. *PNAS* 2010, Dec 28; 107(52):22745-50. Epub 2010 Dec 13. PMID: 21149740 PMCID: PMC3012457

- Nicolau, M., Levine, A.J., and Carlsson, G. 2011 Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. *PNAS* April 26;108 (17) :7265-70. Epub 2011 Apr 11. PMID: PMC3084136
- Markert E. K., Mizuno H., Vazquez A., Levine A. J. Molecular classification of prostate cancer using curated expression signatures. *PNAS* 2011 Dec 27; 108(52):21276-21281. Published online 2011 November 28. PMID: PMC3248553
- Aguirre-Ghiso JA. (2007) Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer* 7, 834-46.
- Artandi SE, DePinho RA. (2010) Telomeres and telomerase in cancer. *Carcinogenesis* 31, 9-18.
- Bierie, B., and Moses, H.L.(2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. *Nat. Rev. Cancer* 6, 506–520.
- Blasco, M.A. (2005). Telomeres and human disease: ageing, cancer and beyond. *Nat. Rev. Genet.* 6, 611–622.
- Burkhardt, D.L., and Sage, J. (2008). Cellular mechanisms of tumour suppression by the retinoblastoma gene. *Nat. Rev. Cancer* 8, 671–682.
- Cho, R.W., and Clarke, M.F.(2008). Recent advances in cancer stem cells. *Curr. Opin. Genet. Dev.* 18, 1–6.
- Ciccia, A., and Elledge, S.J. (2010). The DNA damage response: making it safe to play with knives. *Mol. Cell* 40, 179–204.
- Collado, M., and Serrano, M. (2010). Senescence in tumours: evidence from mice and humans. *Nat. Rev. Cancer* 10, 51–57.
- DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B.(2008). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. *Cell Metab.* 7, 11–20.
- Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat. Rev. Genet.* 8, 286–298.
- Evan, G., and Littlewood, T. (1998). A matter of life and cell death. *Science* 281, 1317–1322.
- Ghebranious, N., and Donehower, L.A.(1998). Mouse models in tumor suppression. *Oncogene* 17, 3385–3400.
- Grivnickov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation, and cancer. *Cell* 140, 883–899.

- Gupta, P.B., Chaffer, C.L., and Weinberg, R.A.(2009). Cancer stem cells: mirage or reality? *Nat. Med.* 15, 1010–1012.
- Harper, J.W., and Elledge, S.J. (2007). The DNA damage response: Ten years after. *Mol. Cell* 28, 739–745.
- Hsu, P.P., and Sabatini, D.M.(2008). Cancer cell metabolism: Warburg and beyond. *Cell* 134, 703–707.
- Hynes, N.E., and MacDonald, G. (2009). ErbB receptors and signaling pathways in cancer. *Cancer Cell* 12, 160–170.
- Ince, T.A., Richardson, A.L., Bell, G.W., Saitoh, M., Godar, S., Karnoub, A.E., Iglehart, J.D., and Weinberg, R.A. (2007). Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. *Cancer Cell* 12, 160–170.
- Jones, P.A., and Baylin, S.B. (2007). The epigenomics of cancer. *Cell* 128, 683–692.
- Jones, R.G., and Thompson, C.B.(2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. *Genes Dev.* 23, 537–548.
- Korkola, J., and Gray, J.W.(2010). Breast cancer genomes—form and function. *Curr. Opin. Genet. Dev.* 20, 4–14.
- Lemmon, M.A., and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases. *Cell* 141, 1117–1134.
- Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease. *Cell* 132, 27–42.
- Lowe, S.W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression. *Nature* 432, 307–315.
- Luo, J., Solimini, N.L.,and Elledge, S.J. (2009). Principles of cancer therapy: Oncogene and non-oncogene addiction. *Cell* 136, 823–837.
- Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., and Shipitsin, M., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 133, 704–715.
- Massagué, J. (2008). TGF β in cancer. *Cell* 134, 215–230.
- Mathew, R., Karantza-Wadsworth, V., and White, E. (2007). Role of autophagy in cancer. *Nat. Rev. Cancer* 7, 961–967.
- Negrini, S., Gorgoulis, V.G., and Halazonetis, T.D. (2010). Genomic instability—an evolving hallmark of cancer. *Nat. Rev. Mol. Cell Biol.* 11, 220–228.

Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat. Rev. Cancer* 9, 265–273.

Ruoslahti, E. (2002). Specialization of tumour vasculature. *Nat. Rev. Cancer* 2, 83–90.

Shay, J.W., and Wright, W.E. (2000). Hayflick, his limit, and cellular ageing. *Nat. Rev. Mol. Cell Biol.* 1, 72–76.

Sherr, C.J., and McCormick, F. (2002). The RB and p53 pathways in cancer. *Cancer Cell* 2, 103–112.

Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R.M., Kesari, S., et al. (2011). Feature Article: Transdifferentiation of glioblastoma cells into vascular endothelial cells. *Proc. Natl. Acad. Sci. USA*, Published online January 24, 2011.

Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 324, 1029–1033.

Warburg, O. (1956). On respiratory impairment in cancer cells. *Science* 124, 269–270.

Warburg, O.H. (1930). *The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem.* (London, UK: Arnold Constable).

Yuan, T.L., and Cantley, L.C. (2008). PI3K pathway alterations in cancer: variations on a theme. *Oncogene* 27, 5497–5510.